Differences in the information about procedures after cold chain disruption provided by pharmaceutical industry to hospital and community pharmacies

Abstract

PurposeTo compare the response of the pharmaceutical industry to information requests from a hospital pharmacy and a community pharmacy regarding the inadvertent exposure of refrigerated medicines (2–8°C) to out-of-range temperatures.MethodsA complete list of all authorised medicines labelled for refrigeration was obtained from the Portuguese Medicines Agency. A standard information request regarding cold chain disruption for refrigerated medicines was sent to pharmaceutical companies from a hospital and a community pharmacy in Portugal. For companies who did not provide a response within the first 45 days, a second request was sent and an additional 45 days were allowed before completing data collection. To compare information received from the drug industry with that contained in the official European labelling, the Summaries of Product Characteristics (SmPCs) were retrieved from the regulatory agencies’ databases. Response rate, response time and information appropriateness were assessed.ResultsA total of 792 medicines marketed by 70 different pharmaceutical companies were included. The hospital pharmacy received 560 (70.7%) responses, with a mean response time of 6.5 days (SD=5.3) for the first request. The community pharmacy obtained a response for 411 (51.9%), with a mean response time of 15.5 days (SD=4.8). More appropriate information was provided to hospital pharmacy requests. SmPCs did not contain complete information regarding the inadvertent exposure of medicines to unrefrigerated conditions.ConclusionsWhen enquired about a specific piece of information, the pharmaceutical industry provided quicker, higher quality and more frequent responses to a hospital pharmacy compared with a community pharmacy.

Empirical Study on the Transparency of Security Risk Information in Chinese Listed Pharmaceutical Enterprises Based on the ANP-DS Method

“…e world public medicine field is concerned with the reality of information transparency. e existing research focuses on the transparent supervision of drug information, transparency of the pharmaceutical industry chain in all aspects, and subject of participation [24][25][26]. For example, Vian et al [27] found that the Medicines Transparency Alliance regulates the procurement of pharmaceuticals, drug policies, and drug supply, and establishes appropriate accountability in member states to promote transparency of drug information.…”